Transforming Growth Factor-β and Long Non-coding RNA in Renal Inflammation and Fibrosis
- PMID: 34054586
- PMCID: PMC8155637
- DOI: 10.3389/fphys.2021.684236
Transforming Growth Factor-β and Long Non-coding RNA in Renal Inflammation and Fibrosis
Abstract
Renal fibrosis is one of the most characterized pathological features in chronic kidney disease (CKD). Progressive fibrosis eventually leads to renal failure, leaving dialysis or allograft transplantation the only clinical option for CKD patients. Transforming growth factor-β (TGF-β) is the key mediator in renal fibrosis and is an essential regulator for renal inflammation. Therefore, the general blockade of the pro-fibrotic TGF-β may reduce fibrosis but may risk promoting renal inflammation and other side effects due to the diverse role of TGF-β in kidney diseases. Long non-coding RNAs (lncRNAs) are RNA transcripts with more than 200 nucleotides and have been regarded as promising therapeutic targets for many diseases. This review focuses on the importance of TGF-β and lncRNAs in renal inflammation, fibrogenesis, and the potential applications of TGF-β and lncRNAs as the therapeutic targets and biomarkers in renal fibrosis and CKD are highlighted.
Keywords: SMADs; TGF-β; inflammation; long non-coding RNA; molecular therapy; renal fibrosis.
Copyright © 2021 Gu, Dou, Huang, Liu and Lan.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures

Similar articles
-
Diverse Role of TGF-β in Kidney Disease.Front Cell Dev Biol. 2020 Feb 28;8:123. doi: 10.3389/fcell.2020.00123. eCollection 2020. Front Cell Dev Biol. 2020. PMID: 32258028 Free PMC article. Review.
-
Central role of dysregulation of TGF-β/Smad in CKD progression and potential targets of its treatment.Biomed Pharmacother. 2018 May;101:670-681. doi: 10.1016/j.biopha.2018.02.090. Epub 2018 Mar 22. Biomed Pharmacother. 2018. PMID: 29518614 Review.
-
TGF-β/Smad and Renal Fibrosis.Adv Exp Med Biol. 2019;1165:347-364. doi: 10.1007/978-981-13-8871-2_16. Adv Exp Med Biol. 2019. PMID: 31399973 Review.
-
Transforming growth factor-β signalling in renal fibrosis: from Smads to non-coding RNAs.J Physiol. 2018 Aug;596(16):3493-3503. doi: 10.1113/JP274492. Epub 2018 Jun 28. J Physiol. 2018. PMID: 29781524 Free PMC article. Review.
-
Smads as therapeutic targets for chronic kidney disease.Kidney Res Clin Pract. 2012 Mar;31(1):4-11. doi: 10.1016/j.krcp.2011.12.001. Epub 2012 Jan 6. Kidney Res Clin Pract. 2012. PMID: 26889404 Free PMC article. Review.
Cited by
-
Renal Fibrosis in Lupus Nephritis.Int J Mol Sci. 2022 Nov 18;23(22):14317. doi: 10.3390/ijms232214317. Int J Mol Sci. 2022. PMID: 36430794 Free PMC article. Review.
-
Inflammation-Induced Klotho Deficiency: A Possible Key Driver of Chronic Kidney Disease Progression.Int J Gen Med. 2025 May 11;18:2507-2520. doi: 10.2147/IJGM.S513497. eCollection 2025. Int J Gen Med. 2025. PMID: 40376197 Free PMC article. Review.
-
Salvia miltiorrhiza Bunge (Danshen) and Bioactive Compound Tanshinone IIA Alleviates Cisplatin-Induced Acute Kidney Injury Through Regulating PXR/NF-κB Signaling.Front Pharmacol. 2022 Mar 24;13:860383. doi: 10.3389/fphar.2022.860383. eCollection 2022. Front Pharmacol. 2022. PMID: 35401224 Free PMC article.
-
Protective effect of quercetin on kidney diseases: From chemistry to herbal medicines.Front Pharmacol. 2022 Sep 2;13:968226. doi: 10.3389/fphar.2022.968226. eCollection 2022. Front Pharmacol. 2022. PMID: 36120321 Free PMC article. Review.
-
Mechanisms of norcantharidin against renal tubulointerstitial fibrosis.Pharmacol Rep. 2024 Apr;76(2):263-272. doi: 10.1007/s43440-024-00578-5. Epub 2024 Mar 12. Pharmacol Rep. 2024. PMID: 38472637 Review.
References
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources